Are GLP-1 agonists useful for non-diabetics?

With BMI > 30 (or > 27 with comorbidities): clear evidence for weight reduction (STEP-1 Trial, Wilding 2021, PMID 33567185: ~15 % body weight in 68 weeks with semaglutide). Side effects serious (nausea, GI problems, rare pancreatitis). For 'mild weight loss' in normal-weight 'optimizers' not indicated — off-label, expensive, risk profile not justified.

What does the data say about CGM for healthy adults?

Mixed. For people without metabolic problems, CGM shows data without clear actionable consequence. Personalized nutrition studies (Zeevi 2015, PMID 26590418) show that glucose responses vary inter-individually — but whether this knowledge improves long-term outcomes is not established. Useful as 2-4 week self-experiment, not as continuous tracking.

What is a 'longevity clinic' and what does it cost?

Private clinics like Function Health, Forward, Marek Health or European counterparts offer extensive blood testing (50-100+ markers), imaging (whole-body MRI), lifestyle coaching, and partly experimental interventions. Cost: $2,000-30,000/year. Valuable with documented risk factors. In young healthy adults often over-diagnostic — false-positive findings lead to unnecessary follow-up investigations.

Is the Bryan Johnson 'Blueprint' protocol worth it?

Bryan Johnson's protocol is an n=1 self-experiment, not an evidence-based program. It combines > 100 interventions (supplements, therapies, hardware), often with thin or absent human evidence per component. Estimated cost: $2M/year. Interesting as inspiration for data discipline, absurd as a recommendation for healthy adults. Focus on the 5 proven levers instead of 100 speculative ones.

What about peptide stacks (BPC-157, TB-500, MOTS-c)?

Hype over evidence. Mechanism in animal models promising, human studies thin to absent, regulatory in DE/EU often grey area (prescription or off-label). Sourcing from the internet quality-wise unreliable. We clearly do not recommend it for wellness use.

Will wearable cortisol sensors be available soon?

Research prototypes exist (sweat-based), commercially reliable wearables for continuous cortisol tracking don't exist in consumer quality in 2026. Lab-based saliva cortisol profiles (3-4 samples over the day) are currently the best method for personal stress monitoring.

Biohacking trends 2026: GLP-1, CGM, longevity clinics

Q: What do AI-powered personalization apps do?

Promising trend. AI-based nutrition and training recommendations get better when built on solid data (CGM, sleep trackers, blood tests). BiohackingAI is part of this trend — we combine live PubMed retrieval with personalization, no hallucinations. Risk with generic apps: recommendations without study sources, often based on one-size-fits-all logic.

Direct answer

Seven 2026 biohacking trends with evidence sorting: 1) GLP-1 agonists (semaglutide, tirzepatide) — real effect at BMI > 30, off-label at normal weight problematic; 2) CGM for healthy adults — interesting as 2-4 week experiment, often overhyped for continuous tracking; 3) longevity clinics — valuable with risk factors, over-diagnostic in young healthy adults; 4) AI-powered personalization — promising trend; 5) Bryan Johnson-style tracking protocols — n=1 spectacle, not evidence-based program; 6) peptide stacks — hype over evidence; 7) continuous cortisol tracking — hardware not ready. Not every trend is a recommendation.

The 7 trends, individually rated

1. GLP-1 agonists (semaglutide, tirzepatide) for non-diabetic weight reduction

What: originally diabetes drugs, now approved for obesity (Wegovy = semaglutide 2.4 mg/week; Zepbound/Mounjaro = tirzepatide). Effect size in Phase III trials: ~15 % body weight in 68 weeks (STEP-1, Wilding 2021, PMID 33567185); tirzepatide even 20 %+.

Who benefits: BMI > 30 or > 27 with comorbidities (hypertension, prediabetes, dyslipidemia). Here clear evidence-based indication, insurers increasingly cover it.

Who should NOT benefit: normal-weight optimizers ("want to lose 3 kg"). Side effects are real: nausea, GI problems, fatigue, rare pancreatitis cases. Off-label sourcing from abroad legally and quality-wise risky.

2. CGM for healthy adults

See innovative methods. Briefly: 2-4 week self-experiment instructive with metabolic symptoms or performance focus. Continuous use in healthy adults without clear data basis.

3. Longevity clinics (Function Health, Forward, Attia model)

What: private clinics with comprehensive blood testing (50-100+ markers), whole-body MRI, DEXA scan, VO2max test, lifestyle coaching, partly experimental interventions (HBOT, stem cells).

Who benefits: adults > 40 with family history (heart attack, cancer), existing risk factors, or those who want thorough tracking.

Risks: false-positive findings from aggressive screening → unnecessary follow-up investigations with their own risks (biopsies, radiation). For young healthy adults mostly over-diagnostic.

Cost: $2,000-30,000/year depending on program depth.

4. AI-powered personalization

Promising trend with real potential. When AI apps build on solid data (CGM, sleep trackers, blood tests, training data), they can generate individually more sensible recommendations than static one-size-fits-all plans. Risk: apps without study sources, often hallucinated recommendations, generic "AI optimization" as marketing buzzword. BiohackingAI is part of this trend — we combine live PubMed retrieval with evidence levels, no hallucinations.

5. Bryan Johnson "Blueprint"-style protocols

Bryan Johnson invests $2M per year in a self-experimental anti-aging program with over 100 interventions. As public performance it's remarkable: he tracks with clinical discipline, documents transparently.

As a recommendation for others it's problematic: most of the > 100 components have thin or absent evidence per individual component. The overall program is an n=1 experiment that doesn't generalize. Focus on the 5-6 proven lifestyle levers (see guide) instead of 100 speculative interventions.

6. Peptide stacks (BPC-157, TB-500, MOTS-c, Epitalon)

Current hype trend. Mechanism in animal models often promising, human studies thin to absent. In DE/EU many of these peptides are prescription-required or in grey area. Off-label sourcing from the internet is quality-wise risky (impurities, wrong dosing, lack of sterility). We clearly do not recommend it for wellness use.

7. Continuous cortisol tracking

Wearables for continuous cortisol measurement are not yet available in consumer quality in 2026. Research prototypes (sweat-based) exist, but accuracy and sensitivity for home use are insufficient. Current state: lab-based saliva cortisol profile (3-4 samples over the day) is the most reliable personal stress-monitoring method.

What we see as "non-trend but underrated"

Boring basics: sleep consistency, strength training, MedDiet, sauna have dense evidence and maximal effect-to-effort. While the influencer world jumps to every new peptide stack, lifestyle basics remain the dominant lever.

Lifestyle audit every 6 months: not a trend but sensible. Blood test (lipid panel, HbA1c, vitamin D, ferritin), steps/sleep data of the past quarters, training consistency. An audit appointment with yourself every six months.

Methodology — how we rate trends

Three questions per trend: a) What effect size is established in human RCTs? b) What risks does the application have in the wellness context (outside clinical indication)? c) What cost-benefit ratio results compared to the basic levers?

A trend gets a cautious recommendation if all three questions can be answered positively. Otherwise: "interesting but too early" or "remains hype".

What are the latest biohacking trends I should check out?